<strong>Objectives:</strong><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> To study the epidemiological, diagnos...<strong>Objectives:</strong><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> To study the epidemiological, diagnostic, therapeutic </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> prognostic aspects of gastric adenocarcinoma at the Joliot Curie Institute in Dakar. </span><b><span style="font-family:Verdana;">Materials and Methods: </span></b><span style="font-family:Verdana;">We conducted a retrospective study over </span><span style="font-family:Verdana;">a seven-year period</span><span style="font-family:Verdana;"> from January 2010 to December 2017 at the Joliot Curie Institute in Dakar. All cases of gastric adenocarcinoma proven by </span><span style="font-family:Verdana;">fibroscopy</span><span style="font-family:Verdana;"> followed by histology or proven on the histological analysis of a surgical specimen were taken into account. The parameters studied were age, risk factors, stages of the disease, treatment </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> prognosis. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> There were 54 cases of gastric adenocarcinoma </span><span style="font-family:Verdana;">over a period of</span><span style="font-family:Verdana;"> 7 years. The average age was 54.74 years with extremes of 25 and 84 years. A male predominance was noted (35/54). The main risk factors found were alcohol (5/54), tobacco (13/54), </span><i><span style="font-family:Verdana;">Helicobacter </span><span style="font-family:Verdana;">pilori</span></i><span style="font-family:Verdana;"> (4/54), gastric ulcer (12/54). Epigastralgia was the most frequent clinical manifestation. </span><span style="font-family:Verdana;">FOGD</span><span style="font-family:Verdana;"> was carried out in 77.8% of patients. Histology was obtained before surgery in 40 patients (74.1% of cases) and </span><span style="font-family:Verdana;">on</span><span style="font-family:Ve展开更多
<strong>Context:</strong> <span><span><span><span><span style="font-family:""><span style="font-family:Verdana;">Technological advances have imp...<strong>Context:</strong> <span><span><span><span><span style="font-family:""><span style="font-family:Verdana;">Technological advances have improved the toxicities of radiotherapy. We are evaluating the 3D technique in prostate cancer. </span><b><span style="font-family:Verdana;">Materials and Methods:</span></b><span style="font-family:Verdana;"> Retrospective study from January 2015 to December 2015 with 29 files. Survival was calculated by Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">We collected 29 patient records over the study period. The median age was 75 years with the following extremes: 54 years and 83 years. The median PSA level was 12 ng/ml with a range of 3.05 to 79 ng/ml. Gleason score analysis showed 6 patients (20.69%) with a score of 6 (3 + 3), 23 patients (79.31%) with a score of 7 including 12 patients (41.38%) with grade 3 and 11 patients (37.93%) with grade 4. The median dose delivered was 74 Gy, with a mean dose of 73.79 Gy and extremes of 70 Gy for the minimum and 76 Gy for the maximum. Hormone therapy was combined with radiotherapy in 17 patients (58.62%). Sev</span><span style="font-family:Verdana;">en patients (24.14%) had grade 1 acute bladder toxicity and one patient</span><span style="font-family:Verdana;"> (3.45%) </span><span style="font-family:Verdana;">had grade 2 acute toxicity. Late bladder toxicity was grade 1 in 5 patients</span><span style="font-family:Verdana;"> (17.24%), grade 2 in 3 patients (10.34%) and grade 3 in 1 patient (3.45%). </span><span style="font-family:Verdana;">Late rectal toxicity, grade 2 in 3 patients (10.34%), grade 3 in 1 patient, was noted. Overall survival at 2 years was 100% and 89.65% at 5 years. Relapse-free </span><span><span style="font-family:Verdana;">survival at 2 years was 82.76% and 62.07% at 5 years. There were 3 deaths (10.34%) of which only one was related to prostate cancer. </span><b><span style="font-family:Verdana;">Conclusion:</span></b></span></span></span><展开更多
文摘<strong>Objectives:</strong><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> To study the epidemiological, diagnostic, therapeutic </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> prognostic aspects of gastric adenocarcinoma at the Joliot Curie Institute in Dakar. </span><b><span style="font-family:Verdana;">Materials and Methods: </span></b><span style="font-family:Verdana;">We conducted a retrospective study over </span><span style="font-family:Verdana;">a seven-year period</span><span style="font-family:Verdana;"> from January 2010 to December 2017 at the Joliot Curie Institute in Dakar. All cases of gastric adenocarcinoma proven by </span><span style="font-family:Verdana;">fibroscopy</span><span style="font-family:Verdana;"> followed by histology or proven on the histological analysis of a surgical specimen were taken into account. The parameters studied were age, risk factors, stages of the disease, treatment </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> prognosis. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> There were 54 cases of gastric adenocarcinoma </span><span style="font-family:Verdana;">over a period of</span><span style="font-family:Verdana;"> 7 years. The average age was 54.74 years with extremes of 25 and 84 years. A male predominance was noted (35/54). The main risk factors found were alcohol (5/54), tobacco (13/54), </span><i><span style="font-family:Verdana;">Helicobacter </span><span style="font-family:Verdana;">pilori</span></i><span style="font-family:Verdana;"> (4/54), gastric ulcer (12/54). Epigastralgia was the most frequent clinical manifestation. </span><span style="font-family:Verdana;">FOGD</span><span style="font-family:Verdana;"> was carried out in 77.8% of patients. Histology was obtained before surgery in 40 patients (74.1% of cases) and </span><span style="font-family:Verdana;">on</span><span style="font-family:Ve
文摘<strong>Context:</strong> <span><span><span><span><span style="font-family:""><span style="font-family:Verdana;">Technological advances have improved the toxicities of radiotherapy. We are evaluating the 3D technique in prostate cancer. </span><b><span style="font-family:Verdana;">Materials and Methods:</span></b><span style="font-family:Verdana;"> Retrospective study from January 2015 to December 2015 with 29 files. Survival was calculated by Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">We collected 29 patient records over the study period. The median age was 75 years with the following extremes: 54 years and 83 years. The median PSA level was 12 ng/ml with a range of 3.05 to 79 ng/ml. Gleason score analysis showed 6 patients (20.69%) with a score of 6 (3 + 3), 23 patients (79.31%) with a score of 7 including 12 patients (41.38%) with grade 3 and 11 patients (37.93%) with grade 4. The median dose delivered was 74 Gy, with a mean dose of 73.79 Gy and extremes of 70 Gy for the minimum and 76 Gy for the maximum. Hormone therapy was combined with radiotherapy in 17 patients (58.62%). Sev</span><span style="font-family:Verdana;">en patients (24.14%) had grade 1 acute bladder toxicity and one patient</span><span style="font-family:Verdana;"> (3.45%) </span><span style="font-family:Verdana;">had grade 2 acute toxicity. Late bladder toxicity was grade 1 in 5 patients</span><span style="font-family:Verdana;"> (17.24%), grade 2 in 3 patients (10.34%) and grade 3 in 1 patient (3.45%). </span><span style="font-family:Verdana;">Late rectal toxicity, grade 2 in 3 patients (10.34%), grade 3 in 1 patient, was noted. Overall survival at 2 years was 100% and 89.65% at 5 years. Relapse-free </span><span><span style="font-family:Verdana;">survival at 2 years was 82.76% and 62.07% at 5 years. There were 3 deaths (10.34%) of which only one was related to prostate cancer. </span><b><span style="font-family:Verdana;">Conclusion:</span></b></span></span></span><
